Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna’s BioMarin Pharmaceuticals BMRN Stock Holding History

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-940	Closed	-$78.7K	–	167
2024 Q1	$78.7K	Hold	940	–	–	0.03%	140
2023 Q4	$90.6K	Buy	+940	New	+$83.2K	0.04%	141

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's BMRN Position: Q2 2024 in Review

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 940 shares — an estimated $78.7K sold.

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $90.6K in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna sold 940 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $78.7K.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's BioMarin Pharmaceuticals position peaked at $90.6K in Q4 2023.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's 13F filing for Q2 2024, filed 29 Aug 2025.